Cellectar to Participate at Upcoming Institutional Investor Conferences
On March 11, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced that its CEO, James Caruso, will present at two upcoming conferences. The Oppenheimer 31st Annual Healthcare Conference is scheduled for March 16, 2021, at 8:00 am ET, with opportunities for 1x1 meetings. The Maxim Group 2021 Emerging Growth Virtual Conference takes place from March 17-19, 2021. Cellectar focuses on cancer treatment drug development, particularly through its Phospholipid Drug Conjugate™ platform.
- None.
- None.
FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conferences:
Oppenheimer 31st Annual Healthcare Conference
| Date: | March 16, 2021 |
| Presentation Time: | 8:00 am ET |
| Available for 1x1 meetings | |
| Webcast: | To register, click on the link HERE |
Maxim Group 2021 Emerging Growth Virtual Conference
| Date: | March 17-19, 2021 |
| Webcast: | To register, click on the link HERE |
The company’s presentation is available for on-demand viewing in the link HERE.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
FAQ
What is the upcoming event for Cellectar Biosciences in March 2021?
When will the Maxim Group 2021 Emerging Growth Virtual Conference be held?
Who will present Cellectar's company overview at the conferences?
What is the focus of Cellectar Biosciences?
What is the Phospholipid Drug Conjugate™ platform?
